Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Korean Journal of Medicine ; : 203-210, 2005.
Article in Korean | WPRIM | ID: wpr-145608

ABSTRACT

BACKGROUND: There still is no standard treatment for the patients with advanced hepatocellular carcinoma. Both doxorubicin and cisplatin have modest activity with the response rates less than 20%, but have synergistic effect. This prospective phase II trial was performed to determine the efficacy and toxicity of doxorubicin and cisplatin combination chemotherapy for patients with advanced hepatocellular carcinoma. METHODS: Patients with advanced hepatocellular carcinoma were entered into this study. Eligibility criteria are described below: histologically proven HCC or mass lesion on radiogram with liver cirrhosis and serum a-fetoprotein level >or=400 ng/mL, UICC stage IV, recurred after any loco-regional treatment, no prior cytotoxic chemotherapy, measurable disease, ECOG performance scale 0~2, age 18~65 year old, adequate bone marrow, cardiac and renal function, total bilirubin

Subject(s)
Humans , Bilirubin , Bone Marrow , Carcinoma, Hepatocellular , Cisplatin , Doxorubicin , Drug Therapy , Drug Therapy, Combination , Liver Cirrhosis , Neutropenia , Prospective Studies , Thrombocytopenia
2.
Korean Journal of Nephrology ; : 175-177, 2002.
Article in Korean | WPRIM | ID: wpr-89947

ABSTRACT

To date, only one case of peritonitis with exit site infection in peritoneal dialysis caused by this micro- organism has been reported. In spite of its apparently benign clinical course, which distinguished it from peritonitis caused by Pseudomonas, this peritonitis relapsed and Comamonas could not be eliminated from the peritoneal liquid, probably due to the persistence of the micro-organism in the exit site. Consequently, peritoneal catheter was removed. In this case, a 68-year-old man was admitted with fever, abdominal tenderness and cloudy peritoneal effluent and empirically treated with antibiotics(cefazolin, tobramycin), intraperitoneally(IP) for 7 days. The first culture was positive for Comamonas acidovorans, sensitive to ceftazidime, cefotetan, ceftriaxone, ciprofloxaxin and imipenem and the perotoneal effluent remained cloudy after 7 days. He was treated with ceftazidime IP, oral ciprofloxacin and nystatin for 26 days. 4 days after the antibiotics treatment, the patient was asymptomatic and the cell count of peritoneal effluent was 50 WBC/mm3 with negative culture. 25 days after the treatment, the patient remained asymptomatic and with 5 WBC/mm3 in peritoneal effluent. Consequently, We experienced a case of peritonitis due to Comamonas acidovorans in a patient on CAPD without exit site infection and managed with preservation of the catheter.


Subject(s)
Aged , Humans , Anti-Bacterial Agents , Catheters , Cefotetan , Ceftazidime , Ceftriaxone , Cell Count , Ciprofloxacin , Comamonas , Delftia acidovorans , Fever , Imipenem , Nystatin , Peritoneal Dialysis , Peritoneal Dialysis, Continuous Ambulatory , Peritonitis , Pseudomonas
SELECTION OF CITATIONS
SEARCH DETAIL